Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagno...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Autores principales: Schmidt, Timothy M., Barwick, Benjamin G., Joseph, Nisha, Heffner, Leonard T., Hofmeister, Craig C., Bernal, Leon, Dhodapkar, Madhav V., Gupta, Vikas A., Jaye, David L., Wu, Jiayi, Goyal, Subir, Chen, Zhengjia, Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6877577/
https://ncbi.nlm.nih.gov/pubmed/31767829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0254-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares